IGM Biosciences Equity 2024

IGM Biosciences Aktienanalyse

What does IGM Biosciences do?

IGM Biosciences Inc was founded in 2010 in Mountain View, California. It is a biopharmaceutical company focused on the development and commercialization of immunotherapy products for the treatment of cancer. Their business model is based on the use of proprietary technology platform to produce high-quality and high-quantity antibody products. The company has different business areas including research and development, antibody production and testing, and marketing and distribution of their products. They offer a wide range of products such as monoclonal antibodies, multi-specific antibodies, and antibody constructs. Their history began with the development of their platform technology, which allows for the production of antibodies with modified properties. This has led to breakthrough products for the treatment of cancer. One of their main products is IGM-2323, a multi-specific antibody targeting solid tumors. It works by binding to two different targets on the cancer cell simultaneously and activating the immune system to destroy the cancer cell. Another important product is IGM-8444, an antibody construct targeting B-cell lymphomas. It has been designed to enhance the immune response to cancer cells by specifically binding to a surface protein on the cancer cells. IGM Biosciences Inc has also formed partnerships with other companies to collaborate on the development of new products. For example, they have partnered with GlaxoSmithKline (GSK) to develop a new class of multi-specific antibodies for the treatment of cancer. Overall, IGM Biosciences Inc has a strong track record and continues to have significant growth potential in the future. Their business model is based on leveraging their proprietary technology platform to develop innovative immunotherapy products for cancer. With a wide range of products and partnerships in the pipeline, it is likely that this company will continue to be successful in the future. IGM Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing IGM Biosciences's Equity

IGM Biosciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding IGM Biosciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating IGM Biosciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

IGM Biosciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in IGM Biosciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about IGM Biosciences stock

What is the equity of IGM Biosciences this year?

IGM Biosciences has equity of 203.23 M USD this year.

What was the equity of IGM Biosciences compared to the previous year?

The equity of IGM Biosciences has increased/decreased by -29.26% decreased compared to the previous year.

What impact does a high equity have on investors of IGM Biosciences?

A high equity is advantageous for investors of IGM Biosciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of IGM Biosciences?

A low equity can be a risk for investors of IGM Biosciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of IGM Biosciences affect the company?

An increase in equity of IGM Biosciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of IGM Biosciences affect the company?

A reduction in equity of IGM Biosciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of IGM Biosciences?

Some factors that can affect the equity of IGM Biosciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of IGM Biosciences so important for investors?

The equity of IGM Biosciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can IGM Biosciences take to change the equity?

To change equity, IGM Biosciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does IGM Biosciences pay?

Over the past 12 months, IGM Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IGM Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of IGM Biosciences?

The current dividend yield of IGM Biosciences is .

When does IGM Biosciences pay dividends?

IGM Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IGM Biosciences?

IGM Biosciences paid dividends every year for the past 0 years.

What is the dividend of IGM Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IGM Biosciences located?

IGM Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von IGM Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IGM Biosciences from 8/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did IGM Biosciences pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of IGM Biosciences in the year 2023?

In the year 2023, IGM Biosciences distributed 0 USD as dividends.

In which currency does IGM Biosciences pay out the dividend?

The dividends of IGM Biosciences are distributed in USD.